Market closed

C4 Therapeutics/$CCCC

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About C4 Therapeutics

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

Ticker

$CCCC
Trading on

Industry

Biotechnology

Employees

145

C4 Therapeutics Metrics

BasicAdvanced
$305M
Market cap
-
P/E ratio
-$1.63
EPS
3.05
Beta
-
Dividend rate
$305M
3.05
$11.88
$3.16
1.4M
6.311
6.144
25.329
27.65
-20.61%
-46.00%
8.28
1.26
1.26
-3.895
65.45%
-40.62%
-0.30%
-3.26%

What the Analysts think about C4 Therapeutics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for C4 Therapeutics stock.

C4 Therapeutics Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

C4 Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CCCC

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for C4 Therapeutics stock?

C4 Therapeutics (CCCC) has a market cap of $305M as of December 14, 2024.

What is the P/E ratio for C4 Therapeutics stock?

The price to earnings (P/E) ratio for C4 Therapeutics (CCCC) stock is 0 as of December 14, 2024.

Does C4 Therapeutics stock pay dividends?

No, C4 Therapeutics (CCCC) stock does not pay dividends to its shareholders as of December 14, 2024.

When is the next C4 Therapeutics dividend payment date?

C4 Therapeutics (CCCC) stock does not pay dividends to its shareholders.

What is the beta indicator for C4 Therapeutics?

C4 Therapeutics (CCCC) has a beta rating of 3.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.